Zeitschrift für Biomarker in der Arzneimittelentwicklung Offener Zugang

Abstrakt

Next-generation sequencing in medication development has been identified in clinical trials

Lanctot Marotta*

The technology of massively parallel or deep sequencing, known as next generation sequencing (NGS), has transformed genomic research. Next-generation sequencing, in comparison to first-generation sequencing, is characterised by high accuracy, rapid speed, and low cost. So far, there are a variety of NGS platforms that use various sequencing technologies. Despite significant differences in engineering, sequencing chemistry, output, accuracy, and cost, all NGS platforms execute parallel sequencing of millions of tiny pieces of DNA. Next-generation sequencing (NGS) is a high-throughput sequencing technique (HTS) that can be used for genome sequencing, re-sequencing, epigenome characterisation, DNA-protein interactions (ChIP-sequencing), and transcriptome profiling (RNA-seq). Next-generation sequencing has now proven to be a useful and efficient method for biosafety assessment. NGS is utilised for a variety of applications, including pathogen safety testing and genetic characterisation, because of its high accuracy and in-depth study of nucleic acid.